LP
CTMX icon

LMR Partners’s CytomX Therapeutics CTMX Stock Holding History

LMR Partners’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.02M Buy
273,213
+38,282
+16% +$146K ﹤0.01% 1047
2026
Q1 		$1.1M Buy
+234,931
New +$1.19M ﹤0.01% 964
2024
Q3 		– Sell
-15,046
Closed -$18.4K – 1338
2024
Q2 		$18.4K Sell
15,046
-3,200
-18% -$6.37K ﹤0.01% 984
2024
Q1 		$39.8K Buy
+18,246
New +$33.7K ﹤0.01% 1000
2022
Q4 		– Sell
-23,134
Closed -$34K – 1138
2022
Q3 		$34K Hold
23,134
– – ﹤0.01% 1130
2022
Q2 		$42K Buy
+23,134
New +$44.3K ﹤0.01% 1174

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

LMR Partners's CTMX Position: Q2 2026 in Review

LMR Partners increased its CytomX Therapeutics (CTMX) stake by 16% in Q2 2026, buying an estimated $146K and bringing the position to 273,213 shares worth $1.02M. The position accounts for ﹤0.01% of the portfolio, ranked #1047.

LMR Partners first reported a position in CTMX in Q2 2022 and has held it in 6 quarters since. The position peaked at $1.1M in Q1 2026. 179 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

  • LMR Partners held 273,213 shares of CytomX Therapeutics worth $1.02M as of Q2 2026.
  • LMR Partners bought 38,282 CytomX Therapeutics shares in Q2 2026, an estimated $146K.
  • CytomX Therapeutics made up ﹤0.01% of LMR Partners's portfolio in Q2 2026, its #1047 holding.
  • LMR Partners first reported a position in CytomX Therapeutics in Q2 2022 and has held it in 6 quarters since.
  • LMR Partners's CytomX Therapeutics position peaked at $1.1M in Q1 2026.
  • 179 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on LMR Partners's 13F filing for Q2 2026, filed 14 Aug 2026.